



11 March 2010
EMA/HMPC/577790/2008
Committee on Herbal Medicinal Products (HMPC)

List of references supporting the assessment of *Echinacea purpurea* (L.) Moench. radix

**This document was valid from 11 March 2010 until May 2017.
It is now superseded by a [new version adopted by the HMPC on 30 May 2017](#) and published on the EMA website.**

The Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Abouelella AM, Shahein YE, Tawfik SS, Zahran AM (2007). Phytotherapeutic effects of *Echinacea purpurea* in gamma-irradiated mice. *J Vet Sci* 8: 341-351.

Agnew LL, Guffogg SP, Matthias A, Lehmann RP, Bone KM, Watson K (2005). *Echinacea* intake induces an immune response through altered expression of leucocyte hsp70, increased white cell counts and improved erythrocyte antioxidant defences. *J Clin Pharm Ther* 30: 363-369.

Barcz E, Sommer E, Nartowska J, Balan B, Chorostowska-Wynimko J, Skopińska-Rózewska E (2007). Influence of *Echinacea purpurea* intake during pregnancy on fetal growth and tissue angiogenic activity. *Folia Histochem Cytobiol* 45(1): 35-39.

Barnes J, Anderson LA, Gibbons S, Phillipson JD (2005). *Echinacea* species (*Echinacea angustifolia* (DC.) Hell., *Echinacea pallida* (Nutt.) Nutt., *Echinacea purpurea* (L.) Moench): A review of their chemistry, pharmacology and clinical properties. *J Pharm Pharmacol* 57: 929-954.

Barnes J, Anderson LA, Phillipson JD (2007). *Echinacea*. In: *Herbal Medicines*, 3rd ed., Pharmaceutical Press, London, UK: 217-236.

Barrett B, Brown RL, Locken K, Maberry R, Bobula JA, D'Alessio D (2002). Treatment of the common cold with unrefined *Echinacea*. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 137: 939-946.

Barrett B, Vohmann M, Calabrese C (1999). *Echinacea* for upper respiratory tract infection. *J Farm Pract* 48: 628-635.

Barrett B (2003). Medicinal properties of *Echinacea*: a critical review. *Phytomedicine* 10: 66-86.

Bauer R, Jurcic K, Puhlmann J, Wagner H (1988). Immunologische *In-vivo-* und *In-vitro-* Untersuchungen mit *Echinacea*-Extrakten. *Arzneim Forsch* 38: 276-281.



Bauer R, Remiger P (1989). TLC and HPLC Analysis of Alkamides in *Echinacea* Drugs. *Planta Med* 1989 55: 367-371.

Bauer R, Remiger P, Jurcic K, Wagner H (1989). Beeinflussung der Phagozytose-Aktivität durch *Echinacea*-Extrakte. *Z Phytother* 10: 43-48.

Bauer R, Liersch R (1993). *Echinacea*. In: Hagers Buch der Pharmazeutischen Praxis, 5th ed., Vol. 5: Drogen E-O, Springer-Verlag, Berlin, Germany: 1-34.

Beuscher N, Schet KH, Bodinet C, Egert D (1990). Modulation of host resistance by polymer substances from *Baptisia tinctoria* and *Echinacea purpurea*. In: Immunotherapeutic prospects of infectious diseases (Masihi KN, Lange W, eds.), Springer-Verlag, Berlin-Heidelberg, Germany: 59-63.

Beuscher N, Bodinet I, Willigmann D, Egert (1995). Immunomodulierende Eigenschaften von Wurzelextrakten verschiedener *Echinacea*-Arten. *Z Phytother* 16: 157-166.

Binns SE, Purgina B, Bergeron C, Smith ML, Ball L, Baum BR, Arnason JT (2000). Light-mediated antifungal activity of *Echinacea* extracts. *Planta Med* 66: 241-244.

Binns SE, Hudson J, Merali S, Arnason JT (2002). Antiviral activity of characterized extracts from *Echinacea* spp. (Heliantheae: Asteraceae) against herpes simplex virus (HSV-I). *Planta Med* 68: 780-783.

Blumenthal M, Goldberg A, Brinckmann J (2000). *Echinacea purpurea* root. In: Herbal Medicine - Expanded Commission E monographs, American Botanical Council, Austin, TX, USA: 98-102.

Bodinet C, Beuscher N (1991). Antiviral and Immunological Activity of Glycoproteins from *Echinacea purpurea* Radix. *Planta Med* 57(2): 33-34.

Bodinet K (1999). Immunopharmacological Untersuchungen an einem pflanzlichen Immunomodulator [Dissertation]. Ernst-Moritz-Arndt-Universität, Greifswald, Germany.

Bodinet C, Freudenstein J (1999). Effect of an orally applied aqueous-ethanolic extract of a mixture of *Thujae occidentalis* herba, *Baptisiae tinctoriae* radix, *Echinaceae purpureae* radix and *Echinaceae pallidae* radix on antibody response against sheep red blood cells in mice. *Planta Med* 65: 695-699.

Bradley P (2006). *Echinacea*. In: British Herbal Compendium, Vol. 2., British Herbal Medicine Association, Bournemouth, UK: 129-141.

Bräunig B, Dorn M, Limburg E, Knick E, Bausendorf (1992). *Echinaceae purpureae* radix: zur stärkung der körpereigenen Abwehr bei grippalen Infekten. *Z Phytother* 13: 7-13.

Brinkeborn RM, Shah DV, Degener FH (1999). Echinaforce® and other *Echinacea* fresh plant preparations in the treatment of the common cold. A randomized, placebo-controlled, double-blind clinical trial. *Phytomedicine* 6: 1-6.

Brousseau M, Miller SC (2005). Enhancement of natural killer cells and increased survival of aging mice fed daily *Echinacea* root extract from youth. *Biogerontology* 6: 157-163.

Budzinski JW, Foster BC, Vandenhoeck S, Arnason JT (2000). An *in vitro* evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. *Phytomedicine* 7: 273-282.

Chen Y, Fu T, Tao T, Yang J, Chang Y, Wang M, Kim L, Qu L, Cassady J, Scalzo R, Wang X (2005). Macrophage Activating Effects of New Alkamides from the Roots of *Echinacea* Species. *J Nat Prod* 68: 773-776.

- Chicca A, Adinolfi B, Martinotti E, Fogli S, Breschi MC, Pellati F, Benvenuti S, Nieri P (2007). Cytotoxic effects of *Echinacea* root hexanic extracts on human cancer cell lines. *J Ethnopharmacol* 110: 148-153.
- Chicca A, Pellati F, Adinolfi B, Matthias A, Massarelli I, Benvenuti S, Martinotti E, Bianucci AM, Bone K, Lehmann R, Nieri P (2008). Cytotoxic activity of polyacetylenes and polyenes isolated from roots of *Echinacea pallida*. *Br J Pharmacol* 153: 879-885.
- Clifford LJ, Nair MG, Rana J, Dewitt DL (2002). Bioactivity of alkamides isolated from *Echinacea purpurea* (L.) Moench. *Phytomedicine* 9: 249-253.
- Currier NL, Miller SC (2000). Natural killer cells from aging mice treated with extracts from *Echinacea purpurea* are quantitatively and functionally rejuvenated. *Exp Gerontol* 35: 627-639.
- Currier NL, Miller SC (2001). *Echinacea purpurea* and melatonin augment natural-killer cells in leukemic mice and prolong life span. *J Altern Complement Med* 7: 241-251.
- Currier NL, Miller SC (2002). The effect of immunization with killed tumor cells, with/without feeding of *Echinacea purpurea* in an erythroleukemic mouse model. *J Altern Complement Med* 8: 49-58.
- Dalby-Brown L, Barsett H, Landbo AK, Meyer AS, Mølgaard P (2005). Synergistic antioxidative effects of alkamides, caffeic acid derivatives, and polysaccharide fractions from *Echinacea purpurea* on *in vitro* oxidation of human low-density lipoproteins. *J Agric Food Chem* 53: 9413-9423.
- Di Carlo G, Nuzzo I, Capasso R, Sanges MR, Galdiero E, Capasso F, Carratelli CR (2003). Modulation of apoptosis in mice treated with *Echinacea* and St. John's wort. *Pharmacol Res* 48: 273-277.
- European Pharmacopoeia (2008). Purple Coneflower Root. In: *European Pharmacopoeia*, 6.0., Vol. 2, Council of Europe. 01/2008: 1824
- European Scientific Cooperative On Phytotherapy (ESCOP) (2003). *Echinaceae purpurae radix*. In: ESCOP Monographs, 2nd ed., Thieme, New York, NY, USA: 137-141.
- European Scientific Cooperative On Phytotherapy (ESCOP) (2009). *Echinaceae purpurae radix*. In: ESCOP Monographs, 2nd ed., Suppl. 2009, Thieme, New York, NY, USA: 102-109.
- Freeman C, Spelman K (2008). A critical evaluation of drug interactions with *Echinacea* spp. *Mol Nutr Food Res* 52: 789-798.
- Gallo M, Sarkar M, Au W, Pietrzak K, Comas B, Smith M, Jaeger TV, Einarsen A, Koren G (2000). Pregnancy outcome following gestational exposure to *Echinacea*: a prospective controlled study. *Arch Intern Med* 160(20): 3141-3143.
- Gertsch J, Schoop R, Kuenzle U, Suter A (2004). *Echinacea* alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. *FEBS Lett* 577: 563-569.
- Goel V, Chang C, Slama J, Barton R, Bauer R, Gahler R, Basu T (2002a). *Echinacea* stimulates macrophage function in the lung and spleen of normal rats. *J Nutr Biochem* 13: 487-492.
- Goel V, Chang C, Slama JV, Barton R, Bauer R, Gahler R, Basu TK (2002b). Alkylamides of *Echinacea purpurea* stimulate alveolar macrophage function in normal rats. *Int Immunopharmacol* 2: 381-387.
- Goel V, Lovlin R, Barton R, Lyon MR, Bauer R, Lee TD, Basu TK (2004). Efficacy of a standardized *Echinacea* preparation (Echinilin) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial. *J Clin Pharm Ther* 29: 75-83.

Goel V, Lovlin R, Chang C, Slama JV, Barton R, Gahler R, Bauer R, Goonewardene L, Basu TK (2005). A proprietary extract from the *Echinacea* plant (*Echinacea purpurea*) enhances systemic immune response during a common cold. *Phytother Res* 19: 689-694.

Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD (2004). The effect of *Echinacea* (*Echinacea purpurea* root) on cytochrome P450 activity *in vivo*. *Clin Pharmacol Ther* 75: 89-100.

Gryzlak BM, Wallace RB, Zimmerman MB, Nisly NL (2007). National surveillance of herbal dietary supplement exposures: the poison control center experience. *Pharmacoepidemiol Drug Saf* 16: 947-957.

Haller CA, Anderson IB, Kim SY, Blanc PD (2002). An evaluation of selected herbal reference texts and comparison to published reports of adverse herbal events. *Adverse Drug React Toxicol Rev* 21: 143-150.

Hellum BH, Nilsen OG (2007). The *in vitro* inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. *Basic Clin Pharmacol Toxicol* 101: 350-358.

Henneicke-von Zepelin H, Hentschel C, Schnitker J, Kohnen R, Köhler G, Wüstenberg P (1999). Efficacy and safety of a fixed combination phytomedicine in the treatment of the common cold (acute viral respiratory tract infection): results of a randomised, double blind, placebo controlled, multicentre study. *Curr Med Res Opin* 15: 214-227.

Hu C, Kitts DD (2000). Studies on the antioxidant activity of *Echinacea* root extract. *J Agric Food Chem* 48: 1466-72.

Huntley AL, Thompson Coon J, Ernst E (2005). The safety of herbal medicinal products derived from *Echinacea* species: a systematic review. *Drug Saf* 28: 387-400.

Jager H, Meinel L, Dietz B, Lapke C, Bauer R, Merkle HP, Heilmann J (2002). Transport of Alkamides from *Echinacea* Species through Caco-2 Monolayers. *Planta Medica* 68: 469-471.

Jurcic K, Melchart D, Holzmann M, Martin P, Bauer R, Doenecke A, Wagner H (1989). Zwei Probandenstudien zur Stimulierung der Granulozytenphagozytose durch *Echinacea*-Extrakt-haltige Präparate. *Z Phytother* 10: 67-70.

LaLone CA, Hammer KD, Wu L, Bae J, Leyva N, Liu Y, Solco AK, Kraus GA, Murphy PA, Wurtele ES, Kim OK, Seo KI, Widrlechner MP, Birt DF (2007). *Echinacea* species and alkamides inhibit prostaglandin E(2) production in RAW264.7 mouse macrophage cells. *J Agric Food Chem* 55: 7314-7322.

Lindenmuth GF, Lindenmuth EB (2000). The efficacy of *Echinacea* compound herbal tea preparation on the severity and duration of upper respiratory and flu symptoms: a randomized, double-blind placebo-controlled study. *J Altern Complement Med* 6: 327-334.

Linde K, Barret B, Bauer R, Melchart D, Woelkart K (2006). *Echinacea* for preventing and treating the common cold. Cochrane Database of Systematic Reviews, Issue 1, In: The Cochrane Library 2008, Issue 3, John Wiley & Sons, Ltd., Chichester, UK: 1-88.

Maffei Facino R, Carini M, Aldini G, Saibene L, Pietta P, Mauri P (1995). Echinacoside and caffeoyl conjugates protect collagen from free radical-induced degradation: a potential use of *Echinacea* extracts in the prevention of skin photodamage. *Planta Med* 61: 510-514.

Matthias A, Gillam EM, Penman KG, Matovic NJ, Bone KM, De Voss JJ, Lehmann RP (2005a). Cytochrome P450 enzyme-mediated degradation of *Echinacea* alkylamides in human liver microsomes. *Chem Biol Interact* 155: 62-70.

- Matthias A, Addison RS, Penman KG, Dickinson RG, Bone KM, Lehmann RP (2005b). *Echinacea* alkamide disposition and pharmacokinetics in humans after tablet ingestion. *Life Sci* 77: 2018-2029.
- Matthias A, Blanchfield JT, Penman KG, Toth I, Lang CS, De Voss JJ, Lehmann RP (2004). Permeability studies of alkylamides and caffeic acid conjugates from *Echinacea* using a Caco-2 cell monolayer model. *J Clin Pharm Ther* 29: 7-13.
- Matthias A, Addison RS, Agnew LL, Bone KM, Watson K, Lehmann RP (2007). Comparison of *Echinacea* alkylamide pharmacokinetics between liquid and tablet preparations. *Phytomedicine* 14: 587-590.
- Matthias A, Banbury L, Bone KM, Leach DN, Lehmann RP (2008). *Echinacea* alkylamides modulate induced immune responses in T-cells. *Fitoterapia* 79: 53-58.
- Mazza G, Cottrell T (1999). Volatile components of roots, stems, leaves, and flowers of *Echinacea* species. *J Agric Food Chem* 47: 3081-3085.
- McCann DA, Solco A, Liu Y, Macaluso F, Murphy PA, Kohut ML, Senchina DS (2007). Cytokine- and interferon-modulating properties of *Echinacea* spp. root tinctures stored at -20°C for 2 years. *J Interferon Cytokine Res* 27: 425-436.
- Meijerman I, Beijnen JH, Schellens JH (2006). Herb-drug interactions in oncology: focus on mechanisms of induction. *Oncologist* 11: 742-752.
- Melchart D, Linde K, Worku F, Bauer R, Wagner H (1994). Immunomodulation with *Echinacea*. A systematic review of controlled clinical trials. *Phytomed* 1: 245-254.
- Melchart D, Linde K, Worku F, Sarkady L, Holzmann M, Jurcic K, Wagner H (1995). Results of five randomized studies on the immunomodulatory activity of preparations of *Echinacea*. *J Altern Complement Med* 1: 145-160.
- Melchart D, Walther E, Linde K, Brandmaier R, Lersch C (1998). *Echinacea* root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial. *Arch Fam Med* 7: 541-545.
- Melchart D, Linde K, Fischer P, Kaesmayr J (2004). *Echinacea* for preventing and treating the common cold (Cochrane review). In: The Cochrane Library, Issue 2, John Wiley & Sons, Chichester, UK.
- Mengs U, Clare CB, Poiley JA (1991). Toxicity of *Echinacea purpurea*. Acute, subacute and genotoxicity studies. *Arzneimittelforschung* 41: 1076-81.
- Merali S, Binns S, Paulin-Levasseur M, Ficker C, Smith M, Baum B, Brovelli E, Arnason JT (2003). Antifungal and Anti-inflammatory Activity of the Genus *Echinacea*. *Pharmaceutical Biology* 41: 412-420.
- Müller-Jakic B, Breu W, Pröbstle A, Redl K, Greger H, Bauer R (1994). *In vitro* inhibition of cyclooxygenase and 5-lipoxygenase by alkamides from *Echinacea* and *Achillea* species. *Planta Med* 60: 37-40.
- Mullins RJ (1998). *Echinacea*-associated anaphylaxis. *Med J Austr* 168: 170-171.
- Mullins RJ, Heddle R (2002). Adverse reactions associated with *Echinacea*: the Australian experience. *Ann Allergy Asthma Immunol* 88: 42-51.
- PDR (2007). *Echinacea*. In: Gruenwald J, Brendler T, Jaenicke C (editors). PDR for herbal medicines, 4th Edition, Thomson Healthcare Inc., Montvale, NJ, USA: 266-276.
- Pellati F, Benvenuti S, Magro L, Melegari M, Soragni F (2004). Analysis of phenolic compounds and radical scavenging activity of *Echinacea* spp. *J Pharm Biomed Anal* 35: 289-301.

Perri D, Dugoua JJ, Mills E, Koren G (2006). Safety and efficacy of *Echinacea* (*Echinacea angustifolia*, *E. purpurea* and *E. pallida*) during pregnancy and lactation. *Can J Clin Pharmacol* 13(3): 262-267.

Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, Altmann KH, Gertsch J (2006). Alkylamides from *Echinacea* are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. *J Biol Chem* 281: 14192-14206.

Raso GM, Pacilio M, Di Carlo G, Esposito E, Pinto L, Meli R (2002). *In-vivo* and *in-vitro* anti-inflammatory effect of *Echinacea purpurea* and *Hypericum perforatum*. *J Pharm Pharmacol* 54: 1379-1383.

Rininger JA, Kickner S, Chigurupati P, McLean A, Franck Z (2000). Immunopharmacological activity of *Echinacea* preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells. *J Leukoc Biol* 68: 503-10.

Romiti N, Pellati F, Nieri P, Benvenuti S, Adinolfi B, Chieli E (2008). P-Glycoprotein inhibitory activity of lipophilic constituents of *Echinacea pallida* roots in a human proximal tubular cell line. *Planta Med* 74: 264-266.

Schoop R, Klein P, Suter A, Johnston SL (2006). *Echinacea* in the prevention of induced rhinovirus colds: a meta-analysis. *Clin Ther* 28: 174-183.

See DM, Broumand N, Sahl L, Tilles JG (1997). *In vitro* effects of *Echinacea* and *Ginseng* on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. *Immunopharmacology* 35: 229-235.

Senchina DS, McCann DA, Asp JM, Johnson JA, Cunnick JE, Kaiser MS, Kohut ML (2005). Changes in immunomodulatory properties of *Echinacea* spp. root infusions and tinctures stored at 4 degrees C for four days. *Clin Chim Acta* 355: 67-82.

Senchina DS, Wu L, Flinn GN, Konopka del N, McCoy JA, Widrlechner MP, Wurtele ES, Kohut ML (2006). Year-and-a-half old, dried *Echinacea* roots retain cytokine-modulating capabilities in an *in vitro* human older adult model of influenza vaccination. *Planta Med* 72: 1207-1215.

Senchina DS, Flagel LE, Wendel JF, Kohut ML (2008). Phenetic comparison of seven *Echinacea* species based on immunomodalutary characteristics. *Econ Bot* 60: 205-211.

Shah SA, Sander S, White CM, Rinaldi M, Coleman CI (2007). Evaluation of *Echinacea* for the prevention and treatment of the common cold: a meta-analysis. *Lancet Infect Dis* 7: 473-480.

Sharma M, Arnason JT, Burt A, Hudson JB (2006). *Echinacea* extracts modulate the pattern of chemokine and cytokine secretion in rhinovirus-infected and uninfected epithelial cells. *Phytother Res* 20: 147-152.

Skaudickas D, Kondrotas AJ, Baltrusaitis K, Vaitiekaitis G (2003). Effect of *Echinacea* (*Echinacea purpurea* (L.) Moench) preparations on experimental prostate gland. *Medicina (Kaunas)* 39: 761-766.

Skaudickas D, Kondrotas A, Baltrusaitis K (2004). The effect of *Echinacea purpurea* extract on sexual glands of male rats. *Medicina (Kaunas)* 40: 1211-1218.

Skwarek T, Tynecka Z, Glowniak K, Lutostanska E (1996). *Echinacea* L. – Inducer of interferons. *Herba Polonica* 42: 110-117.

Sloley BD, Urichuk LJ, Tywin C, Coutts RT, Pang PK, Shan JJ (2001). Comparison of chemical components and antioxidants capacity of different *Echinacea* species. *J Pharm Pharmacol* 53: 849-857.

South EH, Exon JH (2001). Multiple immune functions in rats fed *Echinacea* extracts. *Immunopharmacol Immunotoxicol* 23: 411-421.

- Speroni E, Govoni P, Guizzardi S, Renzulli C, Guerra MC (2002). Anti-inflammatory and cicatrizing activity of *Echinacea pallida* Nutt. root extract. *J Ethnopharmacol* 79: 265-272.
- Stimpel M, Proksch A, Wagner H, Lohmann-Matthes ML (1984). Macrophage activation and induction of macrophage cytotoxicity by purified polysaccharide fractions from the plant *Echinacea purpurea*. *Infect Immun* 46: 845-849.
- Sun LZ, Currier NL, Miller SC (1999). The American coneflower: a prophylactic role involving nonspecific immunity. *J Altern Complement Med* 5: 437-446.
- Thygesen L, Thulin J, Mortensen A, Skibsted LH, Molgaard P (2007). Antioxidant activity of cichoric acid and alkamides from *Echinacea purpurea*, alone and in combination. *Food Chem* 101: 74-81.
- Wacker A, Hilbig W (1978). Virusemmung mit *Echinacea purpurea*. *Planta Med* 33: 89-102.
- Wagner H, Proksch A, Riess-Maurer I, Vollmar A, Odenthal S, Stuppner H, Jurcic K, Le Turdu M, Fang JN (1984). Immunostimulating action of polysaccharides (heteroglycans) from higher plants. *Arzneimittelforschung* 35: 1069-1075.
- Wagner H, Breu W, Willer F, Wierer M, Remiger P, Schwenker G (1989). *In vitro* inhibition of arachidonate metabolism by some alkamides and prenylated phenols. *Planta Med* 55: 566-567.
- Wagner H, Jurcic K (2002). Immunological studies of Revitonil, a phytopharmaceutical containing *Echinacea purpurea* and *Glycyrrhiza glabra* root extract. *Phytomedicine* 9: 390-397.
- Westendorf J (1982). Carito® – *in-vitro* Untersuchungen zum Nachweis spasmolytischer und kontraktiler Einflüsse. *Therapiewoche* 32: 6291-6297.
- WHO (1999). Radix echinaceae. In: WHO monographs on selected medicinal plants, Vol. 1, WHO, Geneva, Switzerland: 128-135.
- Wolters Kluwer Health (2004). *Echinacea*. In: The Review of Natural Products, Wolters Kluwer Health, St. Louis, MO, USA.
- Zhai Z, Liu Y, Wu L, Senchina DS, Wurtele ES, Murphy PA, Kohut ML, Cunnick JE (2007a). Enhancement of innate and adaptive immune functions by multiple *Echinacea* species. *J Med Food* 10: 423-434.
- Zhai Z, Haney D, Wu L, Solco A, Murphy PA, Wurtele ES, Kohut ML, Cunnick JE (2007b). Alcohol extracts of *Echinacea* inhibit production of nitric oxide and tumor necrosis factor-alpha by macrophages *in vitro*. *Food Agric Immunol* 18: 221-236.
- Zoutewelle G, Van Wijk R (1990). Effects of *Echinacea purpurea* extracts on fibroblast populated collagen lattice contraction. *Phytotherapy Research* 4: 77-81.